Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL636115 | 0.81 | AAK1 (0.47) | AAK1TDP1L3MBTL1ALDH1A1TSHR | |
| SCHEMBL15834922 | 0.79 | AAK1 (0.46) | AAK1TDP1L3MBTL1ALDH1A1TSHR | |
| SCHEMBL9292700 | 0.78 | AAK1 (0.45) | AAK1TDP1L3MBTL1ALDH1A1TSHR | |
| SCHEMBL27981095 | 0.78 | AAK1 (0.45) | AAK1TDP1L3MBTL1ALDH1A1TSHR | |
| SCHEMBL396482 | 0.77 | MEN1 (0.56) | TDP1L3MBTL1ALDH1A1TSHRLMNA | |
| SCHEMBL8204476 | 0.77 | PDCD1 (0.46) | TDP1L3MBTL1ALDH1A1TSHRCYP3A4 | |
| SCHEMBL21916001 | 0.77 | ALDH1A1 (0.51) | TDP1L3MBTL1ALDH1A1MAPK1KMT2A | |
| SCHEMBL330776 | 0.77 | TDP1 (0.56) | TDP1L3MBTL1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL15759488 | 0.77 | TDP1 (0.44) | TDP1L3MBTL1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL355454 | 0.75 | CES2 (0.53) | AAK1TDP1L3MBTL1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000040-B1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | EP | disclosed |
| EP-1206471-B1 | INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2006-03-01 | — | — | EP | disclosed |
| US-6911444-B2 | Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | JANSSEN PHARMACEUTICS N.V. (BE) | 2005-06-28 | — | — | US | disclosed |
| US-20050090495-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | LACRAMPE JEAN FERNAND ARMAND (FR) | 2005-04-28 | — | — | US | disclosed |
| US-6867207-B2 | IL-5 inhibiting 6-azauracil derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-03-15 | — | — | US | disclosed |
| US-20040167333-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | LACRAMPE JEAN FERNAND ARMAND (FR) | 2004-08-26 | — | — | US | disclosed |
| US-20030114453-A1 | Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-06-19 | — | — | US | disclosed |
| US-20020072603-A1 | Novel IL-5 inhibiting 6-azauracil derivatives | LACRAMPE JEAN FERNAND ARMAND (FR) | 2002-06-13 | — | — | US | disclosed |
| CN-1262679-A | IL-5 inhibiting 6-azauracil derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2000-08-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167333-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | IL6ST, CXCR5, ALOX5 | AAK1 4510/4885TDP1 4646/4885L3MBTL1 3677/4885 |
| US-20050090495-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | CXCR5, HCAR3, IL6ST | AAK1 4102/4885TDP1 4740/4885L3MBTL1 2350/4885 |
| US-20030114453-A1 | Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | IL5, IL15, IL15RA | AAK1 4021/4885TDP1 4615/4885L3MBTL1 4868/4885 |
| US-20020072603-A1 | Novel IL-5 inhibiting 6-azauracil derivatives | IL6ST, ALOX5, IL5 | AAK1 4518/4885TDP1 4101/4885L3MBTL1 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.